A share price of Verona Pharma Plc ADR [VRNA] is currently trading at $92.70, up 0.54%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VRNA shares have gain 9.52% over the last week, with a monthly amount glided 33.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on April 28, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $100. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on April 21, 2025, and set its price target to $80. On January 10, 2025, ROTH MKM initiated with a Buy rating and assigned a price target of $68 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $50 on October 03, 2024. In a note dated August 26, 2022, Piper Sandler initiated an Overweight rating and provided a target price of $31 on this stock.
Verona Pharma Plc ADR experienced fluctuations in its stock price throughout the past year between $14.14 and $93.74. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $92.70 at the most recent close of the market. An investor can expect a potential drop of -15.86% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.16%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.9 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 91.03 points at the first support level, and at 89.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 94.41, and for the 2nd resistance point, it is at 96.12.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Verona Pharma Plc ADR [NASDAQ:VRNA] is 8.86. Further, the Quick Ratio stands at 8.73, while the Cash Ratio is 7.1. Considering the valuation of this stock, the price to sales ratio is 66.57, the price to book ratio is 34.83.
Transactions by insiders
Recent insider trading involved Hahn Mark W, Chief Financial Officer, that happened on Jun 11 ’25 when 0.4 million shares were sold. President and CEO, ZACCARDELLI DAVID completed a deal on Jun 11 ’25 to sell 0.4 million shares. Meanwhile, Director DAVID ZACCARDELLI bought 50000.0 shares on Jun 11 ’25.
